Literature DB >> 22916642

[Synchronous double primary ovarian tumor in situ].

Francisco Bernárdez Zapata1, Rosa Alicia Jáuregui Meléndrez, Elizabeth Cabrera Carranco.   

Abstract

BACKGROUND: Afinding of primary malignancies of different histological nature in each ovary is a particularly interesting condition since the information available about it is scarce and because there is hardly any consensus about its definition, classification and proper diagnostic-therapeutic approach. CLINICAL CASE: A case of a 49-year-old female patient presenting an abdominal mass with irregular 10 x 10 cm edges that comprises the area between the left illiac fossa and the umbilical scar. An exploratory laparatomy revealed two masses; a 15 cm cystic one in the left ovary, and an 8 cm one in the right ovary. The following histopathological analysis revealed a bilateral papillary carcinoma. A full oncogy-necological surgical protocol for ovarian carcinoma was applied. The last histopathological analysis revealed a clear cell carcinoma in the left ovary, and a moderately differentiated endometrioid carcinoma in the right one.
CONCLUSIONS: A rare case of a synchronous double primary ovarian tumor is reported. Its clinical presentation, diagnosis, treatment and follow-up pose a particular classification issue.

Entities:  

Mesh:

Year:  2012        PMID: 22916642

Source DB:  PubMed          Journal:  Ginecol Obstet Mex        ISSN: 0300-9041


  2 in total

1.  Bilateral synchronous ovarian tumours: an uncommon case and review of the literature.

Authors:  Emre Günakan; Yusuf A Tohma; Asuman N Haberal; Ali Ayhan
Journal:  Prz Menopauzalny       Date:  2018-06-30

Review 2.  Synchronous bilateral primary ovarian cancer with right endometroid carcinoma and left high-grade serous carcinoma: a case report and literature review.

Authors:  Mimori Fujimori; Toshifumi Takahashi; Yuka Furukawa; Atsuhiro Takanashi; Yoshiyuki Iizawa; Masatoshi Jimbo; Shu Soeda; Keiya Fujimori; Kazuyuki Takeichi
Journal:  BMC Womens Health       Date:  2022-04-05       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.